Navigation Links
Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
Date:5/17/2012

CHICAGO, IL (May 16, 2012)For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule. However, in an effort to improve toxicity, standard MVAC has been essentially abandoned in favor of other regimens. All current standard neoadjuvant regimens require 12 weeks of chemotherapy.

Now, final results from a phase II clinical trial at Fox Chase Cancer Centerto be presented at the 2012 American Society of Clinical Oncology Annual Meeting on Saturday, June 2point to a treatment regimen that delivers benefits comparable to those of standard MVAC but without the same time requirement. Preliminary findings from the trial show that when MVAC is administered on an accelerated schedule (six weeks instead of 12), accelerated MVAC (AMVAC) patients experienced similar response rates and lower toxicity.

"Accelerated MVAC is an excellent option in terms of efficiency, quick time to surgery, tolerability, and complete response rate," says Elizabeth Plimack, M.D., a medical oncologist at Fox Chase. "It means less time off work for the patient, and less time elapses between their diagnosis and surgery. We hope that this regimen, which is well tolerated and can be given efficiently and quickly without sacrificing effectiveness, will help improve acceptance of neoadjuvant chemotherapy in the medical oncology and urology community."

Plimack and her colleagues recruited patients with muscle-invasive bladder cancer from Fox Chase and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia. Patients underwent AMVAC every two weeks for six weeks and had a radical cystectomy within 8 weeks of the last chemotherapy.

Of the 33 patients who underwent all three rounds of AMVAC, for whom final data is available, 13 (39.1 percent) had a pathologic complete response at the time of surgery. Pathologic complete response, a common prognostic indicator for bladder cancer, indicates that the pathology evaluation of the resected bladder revealed no cancerous cells. The tumors of an additional three patients (9.1 percent) were downstaged during the pathology evaluation, suggesting that AMVAC had some effect in those patients as well. Final data will be presented at the meeting.

The AMVAC data suggest an accelerated course of chemotherapy before surgery confers comparable benefit as standard, 12-week MVACbut without the high toxicity associated with standard treatment.

The National Cancer Institute estimates that nearly 75,000 people will be diagnosed with bladder cancer in 2012, and nearly 15,000 will die from the disease. Patients who are diagnosed with bladder cancer that has spread into the muscle layer of the bladder wall have significantly lower survival rates than those patients whose tumors are confined to the inside lining of the organ. Existing treatment for invasive bladder cancer is unlikely to cure the disease, though it may prolong the time before the disease progresses or symptoms reappear.

"As medical oncologists, we are able to offer cancer-specific therapy to many of our bladder cancer patients, but unfortunately at this time there are few situations where chemotherapy helps achieve cure," says Plimack. "Neoadjuvant chemotherapy has been shown to provide incremental benefit in what I think is the most important endpoint, which is bladder cancer specific survival at five years. Most patients who are cancer free at five years do not experience a recurrence of their cancer. Our goal is to improve the chance of cure for patients going to cystectomy."

At Fox Chase, Plimack specializes in researching and treating patients with kidney, bladder, prostate and testicular cancers. She often recommends AMVAC to her own patients, and points out that the regimen is the preferred neoadjuvant, or pre-surgery, treatment at many academic centers in the United States and abroad.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Accelerated infant growth increases risk of future asthma symptoms in children
2. UCI-led study links prenatal exposure to stress with accelerated cell aging
3. Increased metabolic rate may lead to accelerated aging
4. Chronic stress of cancer causes accelerated telomere shortening
5. Experts call for accelerated national sodium reduction initiatives
6. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
7. PHNS Implements New Accelerated Claims Resolution Services With iSoftStone
8. Chemotherapys effect on overall survival seems to increase based on tumor size
9. Genetic predictor of breast cancer response to chemotherapy
10. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
11. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
(Date:8/21/2017)... ... , ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse ... Board of Trustees for a three-year term beginning January 1, 2018. , The ... that are committed to the improvement of health in their communities. Founded in 1898, ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, LC ... has assisted multiple clients in successfully passing audits such as Office of Civil ... (AICPA SOC Level 2), and State Data Use Agreement Audits. , HIPAA ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology: